Humira recorded KRW 45.4 billion and the TNF-α inhibitors market increased rapidly 20% up
It is known that domestic biosimilars are cruising in the market of TNF-α inhibitors that can be used in rheumarthritis patients.
TNF-α inhibitors, biosimilar products targeting TNF-α responding to rheumarthritis disorders, are effective and has fewer side effects.
According to the pharmaceutic...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
